MABp1 targeting interleukin‐1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open‐label extension period
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental dermatology 2021-01, Vol.46 (1), p.162-163 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 163 |
|---|---|
| container_issue | 1 |
| container_start_page | 162 |
| container_title | Clinical and experimental dermatology |
| container_volume | 46 |
| creator | Kanni, T. Argyropoulou, M. Dinarello, C. A. Simard, J. Giamarellos‐Bourboulis, E. J. |
| description | |
| doi_str_mv | 10.1111/ced.14333 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2411539163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2468664113</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3533-45e9f6548469d73ff2df61a85617de948b5cf74acd5c420cb904f03a8827b2043</originalsourceid><addsrcrecordid>eNp10Utu1TAUBmALgeilMGADyBITGKS140cSZuW2UKQiJjCOnPj41sVxgh99zNgBbIWNsAhWUl9uO0HiTCwdf_p1pB-h55Qc0DKHI-gDyhljD9CKMimqumbkIVoRRppKdqzdQ09ivCCEMtqIx2iP1YLKltUr9OPj0duF4qTCBpL1G2x9guAgf7X-z_ef9PevssHnVgelwdtkI455WXJQyV6q8gfObuzgAJs5YKWVs1Oe1IBTAJUm8OkNDhCzSxHPBqdzwPMC22inBnAYrhP4aGePFwh21k_RI6NchGd37z768u7k8_q0Ovv0_sP66KwamWCs4gI6IwVvuex0w4yptZFUtULSRkPH20GMpuFq1GLkNRmHjnBDmGrbuhlqwtk-erXLXcL8LUNM_WTjCM4pD3OOfc0pFayjkhX68h96Mefgy3VFyVbKQrfq9U6NYY4xgOmXYCcVbnpK-m1LfWmp_9tSsS_uEvMwle29vK-lgMMduLIObv6f1K9PjneRt_x1n6k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2468664113</pqid></control><display><type>article</type><title>MABp1 targeting interleukin‐1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open‐label extension period</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Kanni, T. ; Argyropoulou, M. ; Dinarello, C. A. ; Simard, J. ; Giamarellos‐Bourboulis, E. J.</creator><creatorcontrib>Kanni, T. ; Argyropoulou, M. ; Dinarello, C. A. ; Simard, J. ; Giamarellos‐Bourboulis, E. J.</creatorcontrib><identifier>ISSN: 0307-6938</identifier><identifier>EISSN: 1365-2230</identifier><identifier>DOI: 10.1111/ced.14333</identifier><identifier>PMID: 32516832</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Immunotherapy ; Monoclonal antibodies ; TNF inhibitors</subject><ispartof>Clinical and experimental dermatology, 2021-01, Vol.46 (1), p.162-163</ispartof><rights>2020 British Association of Dermatologists</rights><rights>Copyright © 2020 British Association of Dermatologists</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3533-45e9f6548469d73ff2df61a85617de948b5cf74acd5c420cb904f03a8827b2043</citedby><cites>FETCH-LOGICAL-c3533-45e9f6548469d73ff2df61a85617de948b5cf74acd5c420cb904f03a8827b2043</cites><orcidid>0000-0003-4713-3911 ; 0000-0002-4537-1556</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32516832$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kanni, T.</creatorcontrib><creatorcontrib>Argyropoulou, M.</creatorcontrib><creatorcontrib>Dinarello, C. A.</creatorcontrib><creatorcontrib>Simard, J.</creatorcontrib><creatorcontrib>Giamarellos‐Bourboulis, E. J.</creatorcontrib><title>MABp1 targeting interleukin‐1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open‐label extension period</title><title>Clinical and experimental dermatology</title><addtitle>Clin Exp Dermatol</addtitle><subject>Immunotherapy</subject><subject>Monoclonal antibodies</subject><subject>TNF inhibitors</subject><issn>0307-6938</issn><issn>1365-2230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp10Utu1TAUBmALgeilMGADyBITGKS140cSZuW2UKQiJjCOnPj41sVxgh99zNgBbIWNsAhWUl9uO0HiTCwdf_p1pB-h55Qc0DKHI-gDyhljD9CKMimqumbkIVoRRppKdqzdQ09ivCCEMtqIx2iP1YLKltUr9OPj0duF4qTCBpL1G2x9guAgf7X-z_ef9PevssHnVgelwdtkI455WXJQyV6q8gfObuzgAJs5YKWVs1Oe1IBTAJUm8OkNDhCzSxHPBqdzwPMC22inBnAYrhP4aGePFwh21k_RI6NchGd37z768u7k8_q0Ovv0_sP66KwamWCs4gI6IwVvuex0w4yptZFUtULSRkPH20GMpuFq1GLkNRmHjnBDmGrbuhlqwtk-erXLXcL8LUNM_WTjCM4pD3OOfc0pFayjkhX68h96Mefgy3VFyVbKQrfq9U6NYY4xgOmXYCcVbnpK-m1LfWmp_9tSsS_uEvMwle29vK-lgMMduLIObv6f1K9PjneRt_x1n6k</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Kanni, T.</creator><creator>Argyropoulou, M.</creator><creator>Dinarello, C. A.</creator><creator>Simard, J.</creator><creator>Giamarellos‐Bourboulis, E. J.</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4713-3911</orcidid><orcidid>https://orcid.org/0000-0002-4537-1556</orcidid></search><sort><creationdate>202101</creationdate><title>MABp1 targeting interleukin‐1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open‐label extension period</title><author>Kanni, T. ; Argyropoulou, M. ; Dinarello, C. A. ; Simard, J. ; Giamarellos‐Bourboulis, E. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3533-45e9f6548469d73ff2df61a85617de948b5cf74acd5c420cb904f03a8827b2043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Immunotherapy</topic><topic>Monoclonal antibodies</topic><topic>TNF inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kanni, T.</creatorcontrib><creatorcontrib>Argyropoulou, M.</creatorcontrib><creatorcontrib>Dinarello, C. A.</creatorcontrib><creatorcontrib>Simard, J.</creatorcontrib><creatorcontrib>Giamarellos‐Bourboulis, E. J.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kanni, T.</au><au>Argyropoulou, M.</au><au>Dinarello, C. A.</au><au>Simard, J.</au><au>Giamarellos‐Bourboulis, E. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MABp1 targeting interleukin‐1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open‐label extension period</atitle><jtitle>Clinical and experimental dermatology</jtitle><addtitle>Clin Exp Dermatol</addtitle><date>2021-01</date><risdate>2021</risdate><volume>46</volume><issue>1</issue><spage>162</spage><epage>163</epage><pages>162-163</pages><issn>0307-6938</issn><eissn>1365-2230</eissn><cop>England</cop><pub>Oxford University Press</pub><pmid>32516832</pmid><doi>10.1111/ced.14333</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0003-4713-3911</orcidid><orcidid>https://orcid.org/0000-0002-4537-1556</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0307-6938 |
| ispartof | Clinical and experimental dermatology, 2021-01, Vol.46 (1), p.162-163 |
| issn | 0307-6938 1365-2230 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2411539163 |
| source | Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Immunotherapy Monoclonal antibodies TNF inhibitors |
| title | MABp1 targeting interleukin‐1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open‐label extension period |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T17%3A54%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MABp1%20targeting%20interleukin%E2%80%901%CE%B1%20in%20hidradenitis%20suppurativa%20ineligible%20for%20adalimumab%20treatment:%20results%20of%20the%20open%E2%80%90label%20extension%20period&rft.jtitle=Clinical%20and%20experimental%20dermatology&rft.au=Kanni,%20T.&rft.date=2021-01&rft.volume=46&rft.issue=1&rft.spage=162&rft.epage=163&rft.pages=162-163&rft.issn=0307-6938&rft.eissn=1365-2230&rft_id=info:doi/10.1111/ced.14333&rft_dat=%3Cproquest_cross%3E2468664113%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2468664113&rft_id=info:pmid/32516832&rfr_iscdi=true |